検索結果

Company Profile | About Senju | SENJU Pharmaceutical

512 FAX：+81-6-6226-0406 Date of Incorporation April 9, 1947 Capital 1,415,500,000 yen Board of Directors Chairman of the BoardYukoh Yoshida President ＆ CEOShuhei Yoshida Chief Operating OfficerTakeshi...

Data And Statistics | About Senju | SENJU Pharmaceutical

e 40.7 40.8 46.4 48.9 48.9 Operating Profit 5.4 6.9 7.4 7.1 2.4 Ordinary Profit 8.0 9.1 8.7 9.1 2.9 Total Assets 75.8 83.9 88.2 98.4 100.2 ＊A new accounting standard for revenue recognition has been a...

お知らせ | 千寿製薬株式会社

or Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition（PDF） September 4, 2025 Senju has develo...

Publications | Research & Development | SENJU Pharmaceutica

cebo-Controlled Phase 1/2 Study of a TRPV1 Antagonist SJP-0132 in Participants With Dry Eye Disease Tomoyuki Wada1, Kazunori Omatsu1, Stephen C. Pflugfelder2 1: Senju Pharmaceutical Co., Ltd, Hyogo, J...

, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that it has entered into a LicensingAgreement for Corneal Esthesiometer Brill in Japan with Brill International (Headquart...